China
· Delayed Price · Currency is CNY RemeGen Statistics
Total Valuation
RemeGen has a market cap or net worth of CNY 21.81 billion. The enterprise value is 23.71 billion.
| Market Cap | 21.81B |
| Enterprise Value | 23.71B |
Important Dates
The last earnings date was Friday, March 28, 2025.
| Earnings Date | Mar 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.35% |
| Shares Change (QoQ) | -0.46% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 338.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.70 |
| PB Ratio | 10.98 |
| P/TBV Ratio | 11.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.15 |
| EV / Sales | 13.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.19 |
Financial Position
The company has a current ratio of 1.05, with a Debt / Equity ratio of 1.34.
| Current Ratio | 1.05 |
| Quick Ratio | 0.64 |
| Debt / Equity | 1.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.94 |
| Interest Coverage | -19.68 |
Financial Efficiency
Return on equity (ROE) is -54.15% and return on invested capital (ROIC) is -19.04%.
| Return on Equity (ROE) | -54.15% |
| Return on Assets (ROA) | -16.15% |
| Return on Invested Capital (ROIC) | -19.04% |
| Return on Capital Employed (ROCE) | -42.91% |
| Revenue Per Employee | 572,478 |
| Profits Per Employee | -489,617 |
| Employee Count | 2,999 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 0.49 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.26% in the last 52 weeks. The beta is 0.37, so RemeGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +1.26% |
| 50-Day Moving Average | 36.57 |
| 200-Day Moving Average | 31.90 |
| Relative Strength Index (RSI) | 70.42 |
| Average Volume (20 Days) | 6,771,388 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RemeGen had revenue of CNY 1.72 billion and -1.47 billion in losses. Loss per share was -2.73.
| Revenue | 1.72B |
| Gross Profit | 1.37B |
| Operating Income | -1.42B |
| Pretax Income | -1.47B |
| Net Income | -1.47B |
| EBITDA | -1.19B |
| EBIT | -1.42B |
| Loss Per Share | -2.73 |
Balance Sheet
The company has 762.49 million in cash and 2.67 billion in debt, giving a net cash position of -1.91 billion.
| Cash & Cash Equivalents | 762.49M |
| Total Debt | 2.67B |
| Net Cash | -1.91B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.99B |
| Book Value Per Share | 3.70 |
| Working Capital | 111.50M |
Cash Flow
In the last 12 months, operating cash flow was -1.11 billion and capital expenditures -265.28 million, giving a free cash flow of -1.38 billion.
| Operating Cash Flow | -1.11B |
| Capital Expenditures | -265.28M |
| Free Cash Flow | -1.38B |
| FCF Per Share | n/a |
Margins
Gross margin is 79.81%, with operating and profit margins of -82.98% and -85.53%.
| Gross Margin | 79.81% |
| Operating Margin | -82.98% |
| Pretax Margin | -85.53% |
| Profit Margin | -85.53% |
| EBITDA Margin | -69.53% |
| EBIT Margin | -82.98% |
| FCF Margin | n/a |
Dividends & Yields
RemeGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.35% |
| Shareholder Yield | 0.35% |
| Earnings Yield | -6.73% |
| FCF Yield | -6.33% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RemeGen has an Altman Z-Score of 1.42. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.42 |
| Piotroski F-Score | n/a |